U-104
Based on 8 publication(s) in Google Scholar
U-104 (SLC-0111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki values of 45.1 nM and 4.5 nM, respectively. U-104 shows a significant delay in tumor growth in mice model.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.95%
- CAS No.: 178606-66-1
- Formule: C13H12FN3O3S
- Masse moléculaire:309.32
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Peptidomimetic Library
HY-L033
-
Drug Repurposing Compound Library
HY-L035
-
Exosomes Compound Library
HY-L072
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Targeted Diversity Library
HY-L099
-
Metabolic Enzyme Compound Library
HY-L146
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) U-104
More- Nat Commun. 2025 Sep 17;16(1):8287. [Abstract]
- Cell Death Dis. 2024 Jan 4;15(1):5. [Abstract]
- Proc Natl Acad Sci U S A. 2025 Oct 28;122(43):e2501825122. [Abstract]
- Anal Chem. 2023 Feb 28;95(8):3940-3950. [Abstract]
- Cancer Sci. 2025 Nov 10. [Abstract]
- bioRxiv. 2024 Mar 25:2024.03.21.586157. [Abstract]
- bioRxiv. 2023 Sep 8.
- Oxid Med Cell Longev. 2023 Jan 31:2023:1367938. [Abstract]
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
Activité biologique
|
CA XII |
CA IX |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
138 μM
Compound: SLC-0111
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs in the presence of hypoxic condition by cytofluorimetric analysis
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs in the presence of hypoxic condition by cytofluorimetric analysis
|
[PMID: 38911163] |
| MDA-MB-231 | IC50 |
18.22 μM
Compound: SLC-0111
|
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by cell counting kit 8 method
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by cell counting kit 8 method
|
[PMID: 38894925] |
| U-87MG ATCC | IC50 |
58 μM
Compound: SLC-0111
|
Antiproliferative activity against human U-87MG cells assessed as reduction in cell growth incubated for 72 hrs in the presence of hypoxic condition by cytofluorimetric analysis
Antiproliferative activity against human U-87MG cells assessed as reduction in cell growth incubated for 72 hrs in the presence of hypoxic condition by cytofluorimetric analysis
|
[PMID: 38911163] |
U-104 (SLC-0111) is a potent exosome inhibitor[3].
U-104 has low inhibition for CA I (Ki=5080 nM) and CA II (Ki=9640 nM)[1].
U-104 (50 μM; for 72 hours) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. U-104 (<50 μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
U-104 (38 mg/kg; i.p.; from 11 to 27 days) significantly delays primary tumor growth and reduces cancer stem cell population in NOD/SCID mice orthotopically implanted with MDA-MB-231 LM2-4Luc+ cells[2].
U-104 (50 mg/kg; oral gavage; continuously for 4 days and suspended for 1 day; from 10 to 30 days) shows a significant delay in tumor growth in Balb/c mice orthotopically implanted with 4T1 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 178606-66-1
-
Appearance Solid
-
Masse moléculaire 309.32
-
Formule C13H12FN3O3S
-
Color White to off-white
-
SMILES
O=S(C1=CC=C(NC(NC2=CC=C(F)C=C2)=O)C=C1)(N)=O
-
Synonyms
SLC-0111
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity. [Abstract]2025 Sep 17;16(1):8287. PMID: 40962798 -
Cell Death Dis
LncRNA ZNF674-AS1 drives cell growth and inhibits cisplatin-induced pyroptosis via up-regulating CA9 in neuroblastoma. [Abstract]2024 Jan 4;15(1):5. PMID: 38177154
U-104 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Jan 4;15(1):5. [Abstract]
Cell colony formation with and without U-104 treatment (left), and bar chart of colony number (right).
U-104 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Jan 4;15(1):5. [Abstract]
The survival rate of cells cultured with different concentrations of U-104 after treatment with 10 μM cisplatin was examined.
-
Proc Natl Acad Sci U S A
2025 Oct 28;122(43):e2501825122. PMID: 41123996
U-104 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2025 Oct 28;122(43):e2501825122. [Abstract]
Hs578T cells cultured in HCO3−/CO2-buffered medium were treated for 24 h with the NBCn1 inhibitor S0859 (10 µM), the CA IX/XII inhibitor U-104 (10 µM) or a combination of the two compounds added directly in the incubator. Cycloheximide was added the last 30 min and the expression of ERK3 was analyzed by western blotting.
-
Anal Chem
Electron Paramagnetic Resonance Implemented with Multiple Harmonic Detections Successfully Maps Extracellular pH In Vivo. [Abstract]2023 Feb 28;95(8):3940-3950. PMID: 36725678
U-104 purchased from MedChemExpress. Usage Cited in: Anal Chem. 2023 Feb 28;95(8):3940-3950. [Abstract]
U-104 (20, 40 mg/kg; i.p; single daily for 24 days) results in tumor growth delay in mouse xenograft models.
-
Cancer Sci
Carbonic Anhydrase 12 as a Novel Prognostic Biomarker and Therapeutic Target for High-Risk Follicular Thyroid Carcinoma. [Abstract]2025 Nov 10. PMID: 41208415
U-104 purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2025 Nov 10. [Abstract]
Cell proliferation experiments showed a dose-dependent effect of U104 on FTC133 cells.
-
bioRxiv
RBM39 degrader invigorates natural killer cells to eradicate neuroblastoma despite cancer cell plasticity. [Abstract]2024 Mar 25:2024.03.21.586157. PMID: 38585889 -
-
Oxid Med Cell Longev
Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer. [Abstract]2023 Jan 31:2023:1367938. PMID: 36760347
U-104 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2023 Jan 31:2023:1367938. [Abstract]
U-104 (0-80 μM). Protein lysates were collected from parental cells overexpressing CA9. Transferrin receptor (TrfR) (as a marker of iron uptake) and ferritin heavy chain (FTH1) (as a marker of iron storage) were analyzed by Western blotting.
Solvant et solubilité
DMSO : ≥ 100 mg/mL (323.29 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lou Y, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011 May 1;71(9):3364-76. [Content Brief]
[2]. Lock FE, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013 Oct 31;32(44):5210-9. [Content Brief]
[3]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2329 mL | 16.1645 mL | 32.3290 mL | 80.8224 mL |
| 5 mM | 0.6466 mL | 3.2329 mL | 6.4658 mL | 16.1645 mL | |
| 10 mM | 0.3233 mL | 1.6164 mL | 3.2329 mL | 8.0822 mL | |
| 15 mM | 0.2155 mL | 1.0776 mL | 2.1553 mL | 5.3882 mL | |
| 20 mM | 0.1616 mL | 0.8082 mL | 1.6164 mL | 4.0411 mL | |
| 25 mM | 0.1293 mL | 0.6466 mL | 1.2932 mL | 3.2329 mL | |
| 30 mM | 0.1078 mL | 0.5388 mL | 1.0776 mL | 2.6941 mL | |
| 40 mM | 0.0808 mL | 0.4041 mL | 0.8082 mL | 2.0206 mL | |
| 50 mM | 0.0647 mL | 0.3233 mL | 0.6466 mL | 1.6164 mL | |
| 60 mM | 0.0539 mL | 0.2694 mL | 0.5388 mL | 1.3470 mL | |
| 80 mM | 0.0404 mL | 0.2021 mL | 0.4041 mL | 1.0103 mL | |
| 100 mM | 0.0323 mL | 0.1616 mL | 0.3233 mL | 0.8082 mL |
U-104 Related Classifications
HY-13513 Related Classifications
Powered by Bioz